FGF21 and metabolic dysfunction-associated steatotic liver disease: Future studies should also explore whether the combined elevation could serve as a prognostic marker for MASLD progression and cardiovascular outcomes in patients with MASLD, as well as whether targeted interventions that modify FGF21 signaling or ketone body metabolism could offer therapeutic potential.